CONCORDBIO.NS Profit & Loss
Concord Biotech Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 3 years on file
(FY2023-24 to FY2025-26)
· fetched 2026-08-23 21:43
| Line item | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|
| Revenue from Operations | ₹1,016.94 Cr. | ₹1,200.09 Cr. | ₹1,054.89 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹33.78 Cr. | ₹44.45 Cr. | ₹52.36 Cr. | OtherIncome |
| Total Income | ₹1,050.72 Cr. | ₹1,244.53 Cr. | ₹1,107.25 Cr. | Income |
| Cost of Materials Consumed | ₹184.54 Cr. | ₹264.31 Cr. | ₹254.35 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹56.74 Cr. | ₹55.99 Cr. | ₹62.61 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-12.08 Cr. | ₹-14.79 Cr. | ₹-71.28 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹123.05 Cr. | ₹138.93 Cr. | ₹176.90 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹2.55 Cr. | ₹0.53 Cr. | ₹0.28 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹53.59 Cr. | ₹54.37 Cr. | ₹74.46 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹233.14 Cr. | ₹249.31 Cr. | ₹264.91 Cr. | OtherExpenses |
| Total Expenses | ₹641.53 Cr. | ₹748.66 Cr. | ₹762.23 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹409.19 Cr. | ₹495.88 Cr. | ₹345.01 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Cr. | ₹0.00 Cr. | ₹-3.28 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹409.19 Cr. | ₹495.88 Cr. | ₹341.74 Cr. | ProfitBeforeTax |
| Tax Expense | ₹104.46 Cr. | ₹122.91 Cr. | ₹85.42 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹308.10 Cr. | ₹371.64 Cr. | ₹259.23 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹308.10 Cr. | ₹371.64 Cr. | ₹260.91 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹29.45 | ₹35.52 | ₹24.78 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹29.45 | ₹35.52 | ₹24.78 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from CONCORDBIO.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).